| Ytd | 22.87% | |
| 1y | 176.49% |
| Open | 28.89 | Prev Close | 29.21 | Low | 28.23 | High | 29.34 | Mkt Cap | 3.73B |
| Vol | 1.11M | Avg Vol | 1.29M | EPS | -3.94 | P/E | N/A | Forward P/E | -8.76 |
| Beta | 0.80 | Short Ratio | 12.61 | Inst. Own | 74.67% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 29.09 | 200-d Avg | 24.42 | 1yr Est | 38.33 |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmac
Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weigh
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational c
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d
HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casda
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a
This is the first study to comprehensively interconnect clinical outcomes from patients receiving a
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d
Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rati
Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight
Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analys
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declin
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises
Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperfor
HC Wainwright & Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:RCUS) with a Buy
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst
Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight t
Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and
Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan,
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal can
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Thursday, 369 companies hit new 52-week lows.
Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording gains
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn